RIVAROXABAN KRKA 2.5 mg FILM-COATED TABLETS
How to use RIVAROXABAN KRKA 2.5 mg FILM-COATED TABLETS
Translated with AI
This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.
Show originalContents of the leaflet
Introduction
Package Leaflet: Information for the User
Rivaroxaban Krka 2.5 mg Film-Coated Tablets EFG
Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.
- Keep this package leaflet, as you may need to read it again.
- If you have any questions, consult your doctor or pharmacist.
- This medication has been prescribed to you only, and you should not give it to others, even if they have the same symptoms as you, as it may harm them.
- If you experience side effects, consult your doctor or pharmacist, even if they are not listed in this package leaflet. See section 4.
Contents of the Package Leaflet
- What is Rivaroxaban Krka and what is it used for
- What you need to know before taking Rivaroxaban Krka
- How to take Rivaroxaban Krka
- Possible side effects
- Storage of Rivaroxaban Krka
- Package Contents and Additional Information
1. What is Rivaroxaban Krka and what is it used for
You are taking Rivaroxaban Krka because
- you have been diagnosed with acute coronary syndrome (a group of disorders that include myocardial infarction and unstable angina, a type of severe chest pain) and your blood tests have shown elevated results in certain heart tests.
Rivaroxaban reduces the risk of having another myocardial infarction in adults, or reduces the risk of death due to heart or blood vessel disease.
You will not be prescribed this medication alone. Your doctor will also instruct you to take:
- aspirin or
- aspirin plus clopidogrel or ticlopidine
or
- you have been diagnosed with a high risk of blood clot formation due to coronary artery disease or peripheral arterial disease that causes symptoms.
Rivaroxaban reduces the risk of blood clot formation (atherothrombotic events) in adults.
You will not be prescribed this medication alone. Your doctor will also instruct you to take aspirin.
In some cases, if you are administered rivaroxaban after an intervention to open a narrowed or closed artery in the leg to restore blood flow, your doctor may also prescribe clopidogrel for you to take in addition to aspirin for a short period of time.
This medication contains the active substance rivaroxaban, which belongs to a group of medications called antithrombotic agents. It works by blocking a coagulation factor (factor Xa) and thus reducing the tendency of blood to form clots.
2. What you need to know before taking Rivaroxaban Krka
Do not take Rivaroxaban Krka
- if you are allergic to rivaroxaban or any of the other components of this medication (listed in section 6)
- if you have excessive bleeding
- if you have a disease or problem in an organ of the body that increases the risk of severe bleeding (e.g., stomach ulcer, brain injury or bleeding, or recent brain or eye surgery)
- if you are taking medications to prevent blood clot formation (e.g., warfarin, dabigatran, apixaban, or heparin), except when switching to another anticoagulant treatment or while receiving heparin through a venous or arterial catheter, to prevent it from becoming blocked
- if you have acute coronary syndrome and have previously had a bleeding or blood clot in the brain (stroke)
- if you have coronary artery disease or peripheral arterial disease and have previously had a bleeding in the brain (stroke) or an obstruction of the small arteries that carry blood to the deep tissues of the brain (lacunar stroke) or have had a blood clot in the brain (non-lacunar ischemic stroke) in the past month
- if you have a liver disease that may increase the risk of bleeding
- if you are pregnant or breastfeeding
Do not take Rivaroxaban Krka and inform your doctorif any of these circumstances apply to you.
Warnings and Precautions
Consult your doctor or pharmacist before starting to take this medication.
This medication should not be used in combination with other medications that reduce blood coagulation, such as prasugrel or ticagrelor, except for aspirin and clopidogrel/ticlopidine.
Be careful with Rivaroxaban Krka
- if you have an increased risk of bleeding, as may occur in the following situations:
- severe kidney failure, as kidney function may affect the amount of medication that acts in your body
- if you are taking other medications to prevent blood clot formation (e.g., warfarin, dabigatran, apixaban, or heparin), when switching to another anticoagulant treatment or while receiving heparin through a venous or arterial catheter, to prevent it from becoming blocked (see section "Other medications and Rivaroxaban Krka")
- bleeding disorder
- very high blood pressure, not controlled by medical treatment
- stomach or intestinal diseases that may cause bleeding, such as stomach or intestinal inflammation, esophageal inflammation (e.g., due to gastroesophageal reflux disease), or tumors located in the stomach, intestines, genital tract, or urinary tract
- a problem in the blood vessels of the back of your eyes (retinopathy)
- a lung disease in which the bronchi are dilated and filled with pus (bronchiectasis) or have had a previous bleeding in the lungs
- you are over 75 years old
- if you weigh less than 60 kg
- you have coronary artery disease with severe symptomatic heart failure
- if you have a heart valve prosthesis
- if you know you have a disease called antiphospholipid syndrome (an immune system disorder that increases the risk of blood clot formation), inform your doctor to decide if it may be necessary to modify the treatment.
Inform your doctor if you have any of these situationsbefore taking this medication. Your doctor will decide if you should be treated with this medication and if you should be kept under closer observation.
If you need surgery
- It is very important to take this medication before and after the operation, exactly at the times indicated by your doctor.
- If your operation requires the placement of a catheter or injection in the spinal column (e.g., for epidural or spinal anesthesia, or pain relief):
- it is very important to take this medication before and after the injection or catheter removal, exactly at the times indicated by your doctor.
- inform your doctor immediately if you experience numbness or weakness in your legs or problems in your intestine or bladder at the end of anesthesia, as urgent attention is necessary.
Children and Adolescents
Rivaroxaban Krka 2.5 mg tablets are not recommended for children and adolescents under 18 years of age.There is not enough information about their use in children and adolescents.
Other medications and Rivaroxaban Krka
Inform your doctor or pharmacist if you are using, have recently used, or may need to use any other medication, including those purchased without a prescription.
- If you are taking
- any medication for a fungal infection (e.g., fluconazole, itraconazole, voriconazole, posaconazole), except if only applied to the skin
- tablets with ketoconazole (used to treat Cushing's syndrome, in which the body produces excess cortisol)
- any medication for bacterial infections (e.g., clarithromycin, erythromycin)
- any antiviral medication for HIV/AIDS (e.g., ritonavir)
- other medications to reduce blood coagulation (e.g., enoxaparin, clopidogrel, or vitamin K antagonists, such as warfarin or acenocoumarol), prasugrel, and ticagrelor (see section "Warnings and Precautions")
- anti-inflammatory medications and pain relievers (e.g., naproxen or aspirin)
- dronedarone, a medication for the treatment of irregular heartbeat
- certain medications for the treatment of depression (selective serotonin reuptake inhibitors (SSRIs) or serotonin and norepinephrine reuptake inhibitors (SNRIs))
If any of the above circumstances apply to you, inform your doctorbefore taking this medication, as the effect of this medication may be increased. Your doctor will decide if you should be treated with this medication and if you should be kept under closer observation.
If your doctor considers that you have a higher risk of developing a stomach or intestinal ulcer, they may recommend that you also use a preventive treatment.
- If you are taking
- any medication for the treatment of epilepsy (phenytoin, carbamazepine, phenobarbital)
- St. John's Wort (Hypericum perforatum), a medicinal plant for the treatment of depression
- rifampicin, an antibiotic
If any of the above circumstances apply to you, inform your doctorbefore taking this medication, as the effect of this medication may be reduced. Your doctor will decide if you should be treated with this medication and if you should be kept under closer observation.
Pregnancy, Breastfeeding, and Fertility
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before taking this medication.
If you are pregnant or breastfeeding, do not take this medication. If there is any possibility that you may become pregnant, use an effective contraceptive method while taking this medication. If you become pregnant while taking this medication, inform your doctor immediately, who will decide how you should be treated.
Driving and Using Machines
This medication may cause dizziness (a common side effect) or fainting (an uncommon side effect) (see section 4, "Possible side effects"). Do not drive, ride a bicycle, or use tools or machines if you are affected by these symptoms.
Rivaroxaban Krka contains sodium
This medication contains less than 1 mmol of sodium (23 mg) per tablet, which is essentially "sodium-free".
3. How to take Rivaroxaban Krka
Follow the instructions for taking this medication exactly as indicated by your doctor. If you are unsure, consult your doctor or pharmacist again.
What dose to take
The recommended dose is one 2.5 mg tablet twice a day. Take this medication at the same time every day (e.g., one tablet in the morning and one in the evening). This medication can be taken with or without food.
If you have difficulty swallowing the tablet whole, consult your doctor about other ways to take this medication. The tablet can be crushed and mixed with water or apple sauce, immediately before taking it.
If necessary, your doctor may also administer the crushed tablet through a gastric tube.
This medication will not be prescribed alone.
Your doctor will instruct you to take aspirin as well. If you receive this medication after an acute coronary syndrome, your doctor may also instruct you to take clopidogrel or ticlopidine.
If you are administered rivaroxaban after an intervention to open a narrowed or closed artery in the leg to restore blood flow, your doctor may also prescribe clopidogrel for you to take in addition to aspirin for a short period of time.
Your doctor will instruct you on the dose to take (usually between 75 and 100 mg of aspirin per day, or a dose of 75 to 100 mg of aspirin plus a daily dose of 75 mg of clopidogrel or a standard daily dose of ticlopidine).
When to start treatment with Rivaroxaban Krka
Treatment with this medication after an acute coronary syndrome should be started as soon as possible, once the acute coronary syndrome has been stabilized, i.e., from 24 hours after hospital admission and when parenteral anticoagulant treatment (by injection) is finished.
Your doctor will instruct you on when to start treatment with this medication if you have been diagnosed with coronary artery disease or peripheral arterial disease.
Your doctor will decide how long you should continue taking the treatment.
If you take more Rivaroxaban Krka than you should
Contact your doctor immediately if you have taken too many tablets of this medication. Taking too much of this medication can increase the risk of bleeding. In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
If you forget to take Rivaroxaban Krka
Do not take a double dose to make up for forgotten doses. If you forget to take a dose, take the next tablet at the usual time.
If you interrupt treatment with Rivaroxaban Krka
Take this medication regularly for the time indicated by your doctor.
Do not interrupt treatment with this medication without first talking to your doctor. If you stop taking this medication, you may increase your risk of having another myocardial infarction, a stroke, or dying from a heart or blood vessel disease.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
4. Possible Adverse Effects
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
Like other similar medicines to reduce blood clot formation, this medicine can cause bleeding that can put the patient's life at risk. Excessive bleeding can cause a sudden drop in blood pressure (shock). In some cases, the bleeding may not be apparent.
Inform your doctor immediately if you experience any of the following symptoms:
Signs of bleeding
- bleeding in the brain or inside the skull (symptoms may include headache, weakness on one side of the body, vomiting, seizures, decreased level of consciousness, and stiffness of the neck. This is a serious medical emergency. Seek medical attention immediately!)
- prolonged or excessive bleeding
- exceptional weakness, fatigue, paleness, dizziness, headache, unexplained swelling, difficulty breathing, chest pain or angina.
Your doctor will decide whether to keep you under closer observation or change your treatment.
Signs of severe skin reactions
- intense skin rashes that spread, blisters, or lesions on the mucous membranes, e.g., in the mouth or eyes (Stevens-Johnson syndrome/toxic epidermal necrolysis).
- drug reaction that causes rash, fever, inflammation of internal organs, blood abnormalities, and systemic disease (DRESS syndrome). The frequency of these adverse effects is very rare (up to 1 in 10,000 people).
Signs of severe allergic reactions
- swelling of the face, lips, mouth, tongue, or throat; difficulty swallowing; hives and difficulty breathing; sudden drop in blood pressure.
The frequencies of severe allergic reactions are very rare (anaphylactic reactions, including anaphylactic shock; may affect up to 1 in 10,000 people) and uncommon (angioedema and allergic edema; may affect up to 1 in 100 people).
General list of possible adverse effects
Frequent(may affect up to 1 in 10 patients)
- decrease in red blood cells that can cause paleness and weakness or difficulty breathing
- stomach or intestinal bleeding, urogenital hemorrhage (including blood in the urine and heavy menstrual bleeding), nasal bleeding, gum bleeding
- bleeding in the eye (including bleeding in the white part of the eye)
- bleeding into a tissue or cavity of the body (hematoma, bruising)
- bloody cough
- bleeding from the skin or under the skin
- bleeding after surgery
- discharge of blood or fluid from a surgical wound
- swelling of the limbs
- limb pain
- alteration of kidney function (may be seen in tests performed by the doctor)
- fever
- stomach pain, indigestion, dizziness or feeling of dizziness, constipation, diarrhea
- low blood pressure (symptoms may include dizziness or fainting when standing up)
- general decrease in strength and energy (weakness, fatigue), headache, dizziness
- rash, itching of the skin
- blood tests may show an increase in some liver enzymes
Uncommon(may affect up to 1 in 100 patients)
- bleeding in the brain or inside the skull (see above, signs of bleeding)
- bleeding into a joint that causes pain and swelling
- thrombocytopenia (low platelet count, cells that help blood clotting)
- allergic reaction, including skin allergic reaction
- alteration of liver function (may be seen in tests performed by the doctor)
- blood tests may show an increase in bilirubin, some pancreatic or liver enzymes, or platelet count
- fainting
- feeling of discomfort
- increased heart rate
- dry mouth
- hives
Rare(may affect up to 1 in 1,000 patients)
- bleeding into a muscle
- cholestasis (decrease in bile flow), hepatitis, including traumatic hepatocellular injury (inflammation or liver damage)
- yellowing of the skin and eyes (jaundice)
- localized swelling
- blood accumulation (hematoma) in the groin as a complication after heart surgery in which a catheter is inserted into the leg artery (pseudoaneurysm)
Very rare(may affect up to 1 in 10,000 people)
- accumulation of eosinophils, a type of granulocytic white blood cells that cause inflammation in the lung (eosinophilic pneumonia)
Frequency not known(frequency cannot be estimated from available data)
- renal failure after severe bleeding
- bleeding in the kidney, sometimes with blood in the urine, which causes the kidneys to malfunction (anticoagulant-related nephropathy)
- increased pressure in the muscles of the legs or arms after bleeding, which causes pain, swelling, altered sensation, numbness, or paralysis (compartment syndrome after bleeding)
Reporting of adverse effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that is not listed in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
5. Storage of Rivaroxaban Krka
Keep this medicine out of sight and reach of children.
Do not use this medicine after the expiration date stated on the packaging and on the blister pack after "CAD". The expiration date is the last day of the month indicated.
This medicine does not require special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Deposit the packaging and medicines you no longer need at the pharmacy's SIGRE point. Ask your pharmacist how to dispose of the packaging and medicines you no longer need. This will help protect the environment.
6. Package contents and additional information
Composition of Rivaroxaban Krka
- The active ingredient is rivaroxaban. Each tablet contains 2.5 mg of rivaroxaban.
- The other ingredients (excipients) are mannitol, microcrystalline cellulose, macrogol, poloxamer, sodium lauryl sulfate, sodium croscarmellose, anhydrous colloidal silica, sodium stearyl fumarate in the core, and hypromellose, macrogol, titanium dioxide (E171), and yellow iron oxide (E172) in the tablet coating. See section 2 "Rivaroxaban Krka contains sodium".
Appearance of the product and package contents
Film-coated tablets of pale yellowish-brown color, round, slightly biconvex, engraved with the mark "2.5" on one side of the tablet. Dimensions: diameter of approximately 6.5 mm.
Rivaroxaban Krka is available in packs containing:
Non-perforated blister: 10, 15, 30, 50, 60, 90, and 100 film-coated tablets.
Perforated unit-dose blister: 10 x 1, 30 x 1, 50 x 1, 60 x 1, 90 x 1, and 100 x 1 film-coated tablets.
Calendarized non-perforated blister: 14, 28, 42, 56, 98, 168, and 196 film-coated tablets.
The patient alert card is included in each pack of this medicine.
Only some pack sizes may be marketed.
Marketing authorization holder
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
Manufacturer
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
TAD Pharma GmbH, Heinz-Lohmann-Straße 5, 27472 Cuxhaven, Germany
You can request more information about this medicine by contacting the local representative of the marketing authorization holder:
KRKA Farmacéutica, S.L., Calle de Anabel Segura 10, 28108 Alcobendas, Madrid, Spain
This medicine is authorized in the member states of the European Economic Area and in the United Kingdom (Northern Ireland) with the following names:
Member state | Medicine name |
Denmark | Rivaroxaban Krka 2.5 mg film-coated tablets |
Portugal | Rivaroxaban Krka 2.5 mg film-coated tablets |
Spain | Rivaroxaban Krka 2.5 mg film-coated tablets EFG |
Sweden | Rivaroxaban Krka 2.5 mg film-coated tablets |
Norway | Rivaroxaban Krka |
Finland | Rivaroxaban Krka 2.5 mg film-coated tablets |
Iceland | Rivaroxaban Krka 2.5 mg film-coated tablets |
Belgium | Rivaroxaban Krka 2.5 mg film-coated tablets |
France | Rivaroxaban Krka 2.5 mg, film-coated tablets |
Ireland | Rivaroxaban Krka 2.5 mg film-coated tablets |
United Kingdom (Northern Ireland) | Rivaroxaban Krka 2.5 mg film-coated tablets |
Netherlands | Rivaroxaban Krka 2.5 mg, film-coated tablets |
Date of the last revision of this leaflet:February 2024
Detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
- Country of registration
- Active substance
- Prescription requiredYes
- Manufacturer
- This information is for reference only and does not constitute medical advice. Always consult a doctor before taking any medication. Oladoctor is not responsible for medical decisions based on this content.
- Alternatives to RIVAROXABAN KRKA 2.5 mg FILM-COATED TABLETSDosage form: TABLET, 15 mgActive substance: rivaroxabanManufacturer: Egis Pharmaceuticals Plc.Prescription requiredDosage form: TABLET, 20 mgActive substance: rivaroxabanManufacturer: Egis Pharmaceuticals Plc.Prescription requiredDosage form: TABLET, 10 mgActive substance: rivaroxabanManufacturer: Towa Pharmaceutical Europe S.L.Prescription required
Online doctors for RIVAROXABAN KRKA 2.5 mg FILM-COATED TABLETS
Discuss questions about RIVAROXABAN KRKA 2.5 mg FILM-COATED TABLETS, including use, safety considerations and prescription review, subject to medical assessment and local regulations.
Frequently Asked Questions